Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Brickell Biotech

Deal consists of up to $9 million in upfront and prospective near-term regulatory milestone payments, $168 million in probable long term regulatory and income milestone payments, moreover tiered get paid out payments on internet revenue to Brickell

Sale demonstrates Brickell’s strategic change into the immunology and inflammation fields proceeds will be made use of to advance Company’s pipeline of just lately obtained novel therapies

BOULDER, Colo., Might 03, 2022 (Globe NEWSWIRE) — Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or “Company”), a clinical-stage pharmaceutical enterprise striving to rework patient lives by developing impressive and differentiated prescription therapeutics for the therapy of autoimmune, inflammatory, and other debilitating health conditions, introduced currently that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Prescription drugs Minimal (ASX: BOT) (“Botanix”), whereby Botanix has acquired the Company’s legal rights to sofpironium bromide, a retrometabolically-made new chemical entity that belongs to a class of drugs referred to as anticholinergics. Sofpironium bromide gel, 15% is a opportunity finest-in-class topical remedy that lately done a U.S. Phase 3 pivotal clinical system for the remedy of main axillary hyperhidrosis, or too much underarm perspiring. Brickell was on observe to submit a New Drug Application (“NDA”) to the U.S. Food and drug administration for sofpironium bromide gel, 15% in mid-2022.

Below the conditions of the arrangement, Botanix has acquired from Brickell all property generally linked to sofpironium bromide. In trade, Brickell will get upfront and likely near-time period regulatory milestone payments over the upcoming 18 months of up to $9 million from Botanix. Brickell also is eligible to receive supplemental achievements-based regulatory and profits milestone payments of up to $168 million and tiered gain out payments ranging from large-single digits to mid-teen digits on internet product sales of sofpironium bromide gel. Selected of these quantities are subject to payments by Brickell to its former licensor. Botanix will be accountable for all even further exploration, improvement, and commercialization of sofpironium bromide globally. In link with the sale of sofpironium bromide, Brickell and Botanix entered into a transition providers settlement whereby Brickell will supply consulting expert services to Botanix via submission and opportunity acceptance of the U.S. NDA for sofpironium bromide gel, 15%.

“We are happy to announce the closing of this transaction with Botanix, whose recognized leadership staff has a solid monitor document of getting Food and drug administration approval for, and properly commercializing, some of the top models in health-related dermatology and aesthetic medicine,” commented Robert Brown, Main Government Officer of Brickell. “This offer allows us to commence unlocking the value of sofpironium bromide by delivering an exceptional pathway for sofpironium bromide gel, 15% to turn into a prospective most effective-in-class therapy for the hundreds of thousands of individuals struggling from major axillary hyperhidrosis with no the substantial investment decision for commercialization needed on our part.”

Mr. Brown ongoing, “Today marks a pivotal working day in Brickell’s evolution, as we now change our strategic target to producing novel therapeutics in the immunology and inflammatory fields. Appropriately, we intend to devote the proceeds and potential potential economics from this sale to carry on advancing our exciting pipeline of novel, probable first-in-course therapies. This contains conducting a initial-in-human Stage 1 clinical research that is on monitor to commence this quarter for our lead DYRK1A inhibitor, BBI-02, and progressing the advancement of our direct STING inhibitor, BBI-10, and other subsequent-generation kinase inhibitors by early preclinical stage scientific studies in 2022.”

Extra specifics of the transaction, which includes similar agreements and issues, will be contained in a Present-day Report on Type 8-K to be filed by the Organization.

Oganesson, LLC served as transaction advisor and Faegre Drinker Biddle & Reath, LLP served as lawful counsel to Brickell in link with the transaction. MTS Health Companions, LP served as transaction advisor and Troutman Pepper Hamilton Sanders, LLP served as legal counsel to Botanix in connection with the transaction.

About Sofpironium Bromide

Sofpironium bromide is a new chemical entity that belongs to a class of medicines known as anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals inside of the nervous procedure that are accountable for a selection of bodily capabilities, which includes activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic medication are supposed to exert their action locally and are likely rapidly metabolized into a significantly less energetic metabolite when absorbed into the blood. Sofpironium bromide gel, 15% has accomplished a U.S. pivotal Stage 3 medical application for the therapy of key axillary hyperhidrosis, and sofpironium bromide gel, 5% is approved in Japan for the very same indicator underneath the manufacturer identify ECCLOCK®.

About Brickell

Brickell Biotech, Inc. is a medical-stage pharmaceutical organization striving to rework client lives by producing modern and differentiated prescription therapeutics for the remedy of autoimmune, inflammatory, and other debilitating diseases. Brickell’s pipeline consists of several enhancement-phase candidates and a slicing-edge platform with wide likely in autoimmune and inflammatory diseases. This contains BBI-02, a Stage 1-ready, likely very first-in-class oral DYRK1A inhibitor with sturdy preclinical validation for the remedy of autoimmune and inflammatory diseases, these kinds of as atopic dermatitis, rheumatoid arthritis and form 1 diabetes, BBI-10, a novel, preclinical phase oral STING inhibitor that has demonstrated dose-dependent cytokine reduction in nonclinical experiments supplying proof of mechanism for the procedure of autoinflammatory and exceptional genetic problems, and a system of up coming-technology DYRK, CLK, LRRK2 and TTK kinase inhibitors with the likely to generate treatments for autoimmune, inflammatory, and other debilitating disorders. Brickell’s govt administration staff and board of administrators bring considerable expertise in products enhancement and world commercialization, possessing served in management roles at large worldwide pharmaceutical companies and biotechs that have created and/or launched profitable products and solutions, such as several that have been to start with-in-course and/or obtained iconic standing, these types of as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, and Juvederm®. Brickell’s approach is to leverage this practical experience to in-license, receive, establish, and commercialize innovative pharmaceutical merchandise that Brickell thinks can meaningfully gain sufferers who are struggling from continual, debilitating disorders that are underserved by available therapies. For extra info, go to

Cautionary Note About Forward-Looking Statements

Any statements made in this press launch relating to long run fiscal, enterprise, and/or exploration and medical performance, conditions, plans, prospective clients, developments, or methods and other these types of matters, together with without the need of limitation, Brickell’s approach future functions long run monetary posture long run liquidity long run income projected expenses benefits of functions the predicted timing, scope, style and design, progress, benefits, and/or reporting of information of ongoing and upcoming non-scientific and clinical trials intellectual assets legal rights, together with the validity, expression, and enforceability of these types of the envisioned timing and/or outcomes of regulatory submissions and approvals and prospective buyers for commercializing any of Brickell’s product candidates, or analysis collaborations with, or steps of, its associates, which includes in Japan, South Korea, the United States, or any other country are ahead-seeking statements in the that means of the U.S. Personal Securities Litigation Reform Act of 1995. In addition, when or if applied in this press release, the words “announces,” “may,” “could,” “should,” “might,” “anticipate,” “reflects,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “will,” consider,” “advance,” “excited,” “aim,” “strive,” “help,” “progress,” “select,” “initiate,” “look ahead,” “promise,” and similar expressions and their variants, as they relate to Brickell or any of Brickell’s companions or third events, may possibly identify forward-wanting statements. Brickell cautions that these ahead-hunting statements are issue to several assumptions, threats, and uncertainties, which transform over time, usually promptly, and in unanticipated methods. Vital aspects that may perhaps lead to true success to differ materially from the outcomes talked about in the ahead-searching statements or historical expertise include things like threats and uncertainties, which include without having limitation, study results and information that do not meet targets, anticipations or regulatory approval prerequisites capability to receive satisfactory financing for product progress, regulatory submissions, and any commercialization capacity to keep and implement intellectual residence rights prospective delays or alterations in products progress, trials of any kind, and regulatory submission and evaluations modifications in regulation or plan litigation, regulatory agency opinions or requests source chain disruptions unanticipated requires on dollars means disruptions and destructive consequences connected to the COVID-19 pandemic and the conflict in Ukraine interruptions, disruption, or lack of ability by Brickell or its partners to get or provide investigation materials, uncooked materials, and/or product or service wherever in the environment initiatives to get and keep sufficient pricing and satisfactory reimbursement and other insurance coverage protection for Brickell’s solutions the result of Brickell’s recent and prepared preclinical and scientific trials across its portfolio the inability of Botanix to accomplish the regulatory and income-primarily based events, and for that reason Brickell not getting any extra payments, below its arrangement with them and other challenges affiliated with producing and obtaining regulatory acceptance for, and commercializing, product or service candidates.

Even further information on the factors and challenges that could trigger actual outcomes to vary from any forward-wanting statements are contained in Brickell’s filings with the United States Securities and Trade Fee, which are available at (or at The ahead-hunting statements represent the estimates of Brickell as of the day hereof only. Brickell specifically disclaims any duty or obligation to update ahead-searching statements.

Brickell Trader Get in touch with:
Dan Ferry
LifeSci Advisors
(617) 430-7576
[email protected]